MRK — Merck & Co., Inc.

Sell-side is solidly constructive - 26 buys, 11 holds, 1 sell, a $158.12 average price target and $153.42 recent average versus a $143.94 share price as of 2026-09-13. Q2 2026 (reported 2026-08-04) beat on sales at $16.61B (+5% YoY, ~$200M above consensus) and management raised and narrowed FY26 revenue guidance to $66.3-67.3B, with Winrevair +75% to $588M and FDA approval of Lipfendra, the first oral PCSK9 inhibitor. That optimism is partially capped by the $6.8B (~$2.31/share) Terns Pharmaceuticals charge that drove a GAAP loss of $0.54 and a non-GAAP loss of $0.13, and by non-GAAP FY26 EPS guidance cut to $2.66-2.76 to absorb the deal costs - which explains the -4.26% week and the drift back below the 20-day SMA even as the 3- and 6-month trend stays strongly positive.

The top line is quietly re-accelerating: revenue went $15.62B (Q1'25) -> $15.80B (Q2'25) -> $17.18B (Q3'25) -> $16.32B (Q4'25) -> $16.29B (Q1'26) -> $16.61B (Q2'26), so YoY growth stepped from +4.3% in Q1'26 to +5.1% in Q2'26. Reported profitability, however, inflected violently negative: operating income swung from +$6.71B/+$6.36B in Q1'25/Q2'25 to -$1.88B/-$0.68B in Q1'26/Q2'26, and net income from +$5.08B/+$4.43B to -$4.24B/-$1.34B. That swing is almost entirely one-time R&D/IPR&D and M&A charges, not operating deterioration - R&D jumped to $12.56B in Q1'26 (vs $3.12B a year earlier) and $9.74B in Q2'26 (vs $3.54B). Cash flow tells the opposite and more reliable story: operating cash flow rose to $5.37B in Q2'26 from $3.29B in Q2'25 and free cash flow to $4.48B from $2.53B, and the accruals ratio of -5.17% (as of 2026-06-30) confirms cash is running AHEAD of reported profit. Gross margin slipped modestly to 73.5% in Q2'26 from 75.7% in Q2'25, a mild mix/pricing headwind rather than a structural break. Bottom line: a stable-to-improving revenue and cash trend, with reported earnings optically broken by two quarters of acquisition accounting.

The headline multiples are noise, not signal. TTM P/E of 114.2x and PEG of -1.42 are artifacts of charge-depressed TTM EPS of $1.284, and the 'forward' consensus EPS of $2.746 (matching FY26 non-GAAP guidance of $2.66-2.76) implies a nonsensical ~52x forward P/E - that figure is itself a trough number. Normalized earnings power is closer to 2025's GAAP diluted EPS of $7.28 (the four 2025 quarters summed to $2.01+$1.76+$2.32+$1.19), which puts MRK at roughly 17-20x normalized rather than 114x. On cash, $355.5B of market cap against TTM free cash flow of $16.06B is a 4.5% FCF yield / ~22x P/FCF. The one clean 'expensive' signal is price/sales of 5.35x versus a 5-year average of 4.26x - roughly a 26% premium to its own history - and price/book of 8.49x. Net read: roughly fair to modestly full, with the stock's own history offering no bargain cushion.

The market is deliberately looking through reported earnings: nobody is underwriting a $1.28 TTM EPS pharma at 114x. What the $143.94 price (as of 2026-09-13) actually discounts is (a) that the ~$16B of 2026 one-time R&D/M&A charges do not recur, and (b) that the post-Keytruda portfolio - Winrevair growing 75%, Animal Health growing 8%, the oral PCSK9 Lipfendra launch, the Moderna cancer vaccine partnership - can absorb the late-decade LOE. The 24.5% six-month run suggests the 'cliff is manageable' narrative is already meaningfully priced. The asymmetry is that the stock is not being paid for a downside case: if the Q3 2026 print (late Oct/early Nov) shows the guidance cut was genuinely M&A-only, estimates normalized higher and the stock grinds up; if Keytruda erosion post-2028 proves faster than modeled, the entire normalized-earnings framework that justifies $144 gets repriced down quickly.

As of 2026-09-13, RSI(14) sat at 50.4 - dead neutral, neither exhausted nor washed out. Price at $143.94 was 2.6% below the 20-day SMA (~$147.8), 5.8% above the 50-day (~$136.1) and 20.5% above the 200-day (~$119.4), having returned -4.26% in a week against +8.28% in a month, +20.9% in three months and +24.5% in six. That combination - flat RSI, stretched 200-day spread, recent 20-day breakdown - is a normal consolidation inside a strong uptrend, not a distribution top. Entry implication: the stock is at ~84% of its 52-week range ($77.58-$156.92), so chasing here is late; the higher-quality entry is a pullback toward the 50-day SMA near $136, which is also near where the risk/reward on normalized earnings turns favorable.

• The Keytruda patent cliff (late-decade LOE) remains the dominant valuation framework for the entire sector's view of Merck - Keytruda plus Qlex generated $8.37B in Q2 2026, roughly half of total revenue, and the multiple will stay capped until the replacement revenue stream is proven.
• U.S. drug-pricing/IRA Medicare negotiation and global pricing scrutiny are a persistent structural margin headwind across large-cap pharma, only partly offset by Merck's specialty/oncology mix.
• Balance-sheet and rate environment: long-term debt rose to $51.08B at 2026-06-30 from $33.47B at 2025-03-31, funding an active bolt-on M&A program (Terns, Cidara) at elevated rates, with cash falling to $6.85B from $18.17B at 2025-09-30.
• A vigorous large-pharma M&A cycle - Merck is a buyer deploying cash flow into oncology/hematology assets, which mechanically converts balance-sheet capacity into GAAP charges and goodwill and temporarily obscures underlying earnings.
• Merck's very low beta (0.226) and 2.92% dividend yield make it a defensive/risk-off beneficiary, which means it can lag in high-beta rallies and attract flows for reasons unrelated to its own fundamentals.

• Q3 2026 earnings (tentatively late October/early November 2026) - the first clean checkpoint on whether the FY26 EPS guidance cut to $2.66-2.76 was strictly M&A-related, and on the Winrevair and Keytruda Qlex adoption curves.
• Continued Winrevair ramp (already $588M in Q2 2026, +75% YoY) and the commercial launch of Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor.
• Late-stage pipeline readouts, specifically phase data for remigromig in diabetic eye disease and ongoing trials from the Moderna mRNA cancer vaccine partnership.
• Further business development - additional bolt-on acquisitions (following Terns and Cidara) or partnership deals that bring forward post-Keytruda revenue.
• Any clarity on Keytruda patent litigation, subcutaneous conversion (Qlex) and IRA price-negotiation outcomes, which would de-risk the single largest overhang.

• Keytruda concentration: ~$8.37B of quarterly revenue in one franchise facing a late-decade patent expiration, with no guarantee the pipeline replacements (Winrevair, Lipfendra, remigromig, mRNA cancer vaccine) scale fast enough to cover the gap.
• Serial M&A without proven returns - $6.8B for Terns alone, plus Cidara - has pushed long-term debt from $33.47B (Q1'25) to $51.08B (Q2'26) and produced heavy GAAP charges; capital allocation risk is now a live part of the thesis.
• Valuation optics: P/E of 114x, P/B of 8.49x, EV/EBITDA of 29.1x and P/S of 5.35x versus a 5-year average of 4.26x leave no cushion if the earnings normalization the market is assuming slips a year or two.
• Cash-return coverage: TTM free cash flow of $16.06B against an indicated ~2.92% dividend yield implies roughly $10B+ of annual dividend cost, and free cash flow fell from $18.10B in 2024 to $12.36B in 2025 - coverage is adequate but not ample if M&A spending continues.
• Regulatory and pricing pressure (IRA Medicare negotiation, global price controls) plus FX: Q2 2026 reported growth of 5% versus 4% ex-FX means FX was a modest tailwind that can reverse.

Merck is a high-quality, low-beta, cash-generative pharma with a 2.9% dividend, genuine pipeline momentum (Winrevair +75%, Lipfendra approval, the Moderna partnership) and an equity story that is fundamentally about managing the Keytruda LOE - and at $143.94 as of 2026-09-13, after a 24.5% six-month run and with the stock 20.5% above its 200-day SMA, that story is already largely in the price. Trailing earnings are a mess of one-time M&A charges, but cash flow is improving and the accruals ratio of -5.17% shows reported profit understates reality, not the reverse - so this is not a broken business being priced as one. The honest read is 'fair, not cheap': I would not chase here, but I would be a buyer of weakness toward the 50-day SMA in the mid-$130s, where 18x normalized earnings power offers a real margin of safety against LOE-driven estimate resets. This is analysis, not personalized financial advice.

Two-method blend, 50/50: (1) 18.0x forward P/E on my normalized FY2027 EPS estimate of $8.20 - anchored to 2025's actual GAAP diluted EPS of $7.28 (sum of $2.01+$1.76+$2.32+$1.19) grown for low-single-digit revenue compounding and stripped of the 2026 one-time M&A charges, at a multiple I'd justify for a ~5%-growth large-cap pharma carrying LOE risk = $147.60; and (2) a required 4.4% free-cash-flow yield applied to ~$16.2B of normalized annual FCF (TTM FCF was $16.06B, with OCF improving to $5.37B in Q2 2026) = $368B of equity value over ~2.47B shares = $149.10. Blending gives ~$148.35, rounded to $148 - roughly 3% above the 2026-09-13 price of $143.94 and below the $158.12 sell-side consensus, reflecting that the stock is fairly valued rather than cheap.